Visit main University website

University of Sydney logo

Find MND Biomarker

University of Sydney logo

Find MND Biomarker

↑

Find MND Biomarker

Welcome to FindMNDBiomarker, an integrative database that consolidates the proteomic findings in brain tissue and biofluids (CSF and blood) from patients with motor neuron disease (also known as amyotrophic lateral sclerosis). FindMNDBiomarker is designed for users to quickly assess whether their proteins of interest have been identified in other cohorts and biosamples from patients with MND/ALS.

Purpose: The goal of this search platform is to facilitate the comparison and discovery of proteins that may serve as promising and reproducible biofluid biomarkers of brain-specific changes in MND/ALS and to identify markers that should be further targeted for analyses and validation.

Using this database: Searches can be performed by entering the protein UniProt IDs, names and sample types into the relevant search term box using free text entry. For example, entering ‘NEFL’ will generate a list of all publications in which NEFL was identified to be significantly dysregulated.

A searchable and filterable table is provided with the following columns:

  • Name: Gene name corresponding to the UniProt ID
  • UniProt ID: UniProt accession number
  • Publication: Study Reference
  • Condition: e.g.ALS – Control, ALS Fast – ALS Slow
  • Sample Type: Sample type used (Abbreviations: SMNs, single motor neurons; AH, anterior horn; PH, posterior horn)
  • Regulation: Direction of change (upregulated or downregulated)
  • Cohorts: Cohort size used for each study
  • Average age at onset ± standard deviation/age range: Average age at onset of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average age at collection ± standard deviation/age range: Average age at collection of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average PMI (range) (hours): Average postmortem interval with range (if provided by tissue studies)

To cite this database: Further details and application of this search tool are described in our manuscript “title” that can be located with this DOI:

The FindMNDBiomarker Program: Protein Changes in Motor Neuron Disease/Amyotrophic Lateral Sclerosis Postmortem Tissue and Biofluids 

DOI: https://doi.org/10.1002/ana.27300

Contact: For help contact [email protected]
Sort by:
Total Records Found: 4574, showing 100 per page
Biomarker NameUniProt IDPublicationDisease GroupComparator GroupSample TypeRegulationCohortsAverage age at onsetAverage age at collectionAverage PMI
DCUN1D2 Q6PH85 Chia et al. 2025 ALS-C9orf72 ALS-non-C9orf72 Plasma Up 29 ALS-C9ord72, 202 ALS-non-C9orf72 N/A N/A N/A
DCUN1D2 Q6PH85 Chia et al. 2025 ALS-C9orf72 ALS-non-C9orf72 and Control Plasma Up 29 ALS-C9ord72, 202 ALS-non-C9orf72 plus 383 control N/A N/A N/A
DCUN1D1 Q96GG9 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
DCLK1 O15075 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
DCD P81605 Chen et al. 2016 ALS Control CSF Down 35 ALS, 10 control N/A 52.7 ±12.13 N/A
DCC P43146 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Down 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
DCBLD2 Q96PD2 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
DBT P11182 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
DBNL Q9UJU6 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
DBN1 Q16643 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
DBN1 Q16643 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
DBN1 Q16643 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
DBI P07108 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
DBI P07108 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Down 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
DBI P07108 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
DBI P07108 Seyfried et al. 2018 ALS Control Prefrontal cortex Down 8 ALS, 8 control 60 63.5 9.1
DARS1 P14868 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
DAG1 Q14118 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
DAAM1 Q9Y4D1 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
DAAM1 Q9Y4D1 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
CYTL1 Q9NRR1 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Up 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
CYTL1 Q9NRR1 Zhou et al. 2023 BO-ALS SO-ALS CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS) N/A
CYTH3 O43739 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
CYTC P01034 Vilardo et al. 2024 ALS (validation cohort) ALS (validation cohort) Plasma EVs Up 61 ALS, 30 control N/A 62.88 ± 12.60 N/A
CYRIB Q9NW21 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
CYR61 O00622 Zhou et al. 2023 SO-ALS Control CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS) N/A
CYP4Z2P Q8N1L4 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
CYFIP2 E7EVJ5 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CYCS P99999 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
CYCS P99999 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CYC1 P08574 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CYBB P04839 Oeckl et al. 2020 ALS Control Spinal cord Up 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
CYBA P13498 Oeckl et al. 2020 ALS Control Spinal cord Up 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
CYB5R3 B1AHF3 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Down 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
CYB5R1 Q9UHQ9 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
CYB5R1 Q9UHQ9 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CYB5B O43169 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
CXorf36 Q9H7Y0 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CXCL3 P19876 Berrone et al. 2023 ALS Control Plasma Up 16 ALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS) N/A
CXCL16 Q9H2A7 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CXCL12 P48061 Trautwig et al. 2025 C9orf72 ALS Control CSF Up 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
CXCL12 P48061 Trautwig et al. 2025 Sporadic ALS Control CSF Up 35 sALS, 44 control 53.9 ± 11.5 56.7 ± 10.9 N/A
CXCL12 Q8UUJ9 Berrone et al. 2023 sALS Control Plasma Up 8 sALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS) N/A
CXCL12 P48061 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Up 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
CUTA O60888 Trautwig et al. 2025 C9orf72 ALS Control CSF Down 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
CUTA O60888 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A
CUTA O60888 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Down 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
CUEDC2 Q9H467 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Down 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
CUEDC2 Q9H467 Trautwig et al. 2025 C9orf72 ALS Control CSF Down 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
CUEDC2 Q9H467 Trautwig et al. 2025 C9orf72 ALS C9orf72 ALS Asymptomatic CSF Down 10 C9-ALS, 6 C9-ALS Asymptomatic 56.4 ± 8.9 57.2 ± 8.7, 51.5 ± 18.5 N/A
CTSS P25774 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CTSS P25774 Zhou et al. 2023 SO-ALS Control CSF Down 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS) N/A
CTSH P09668 Oeckl et al. 2020 ALS Control Spinal cord Up 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
CTSH P09668 Katzeff et al. 2020 ALS Control Serum Up 28 ALS, 22 control N/A 52.7 N/A
CTSG P08311 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Down 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
CTSD P07339 Zubiri et al. 2018 ALS fast (late stage) ALS slow (late stage) Plasma Down 6 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow) N/A N/A
CTSD P07339 Collins et al. 2015 ALS Control CSF Down 90 ALS, 80 control N/A N/A N/A
CTSC P53634 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
CTSB P07858 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
CTSB P07858 Collins et al. 2015 ALS Control CSF Down 90 ALS, 80 control N/A N/A N/A
CTNNB1 B4DGU4 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CTNNA2 P26232 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CTNNA1 P35221 Oeckl et al. 2020 ALS Control Spinal cord Up 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
CTGF P29279 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CTBS Q01459 Collins et al. 2015 ALS Control CSF Down 90 ALS, 80 control N/A N/A N/A
CTBS Q01459 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Down 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
CTBS Q01459 Trautwig et al. 2025 C9orf72 ALS C9orf72 ALS Asymptomatic CSF Up 10 C9-ALS, 6 C9-ALS Asymptomatic 56.4 ± 8.9 57.2 ± 8.7, 51.5 ± 18.5 N/A
CTBP2 P56545 Oeckl et al. 2020 ALS Control Spinal cord Up 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
CSTF2 E9PID8 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Up 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
CSTB P04080 Trautwig et al. 2025 C9orf72 ALS Control CSF Up 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
CSTB P04080 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CSTB P04080 Guise et al. 2024 ALS Control Spinal cord (SMNs) Down 3 ALS, 3 control N/A 69.3 9.2
CSTB P04080 Leoni et al. 2019 BO-ALS LO-ALS PBMCs Down 12 BO-ALS, 12 LO-ALS (39-76) (BO-ALS), (33-81) (LO-ALS) N/A N/A
CSTB P04080 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CSTB P04080 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A
CST6 Q15828 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CST4 P01036 Trautwig et al. 2025 C9orf72 ALS C9orf72 ALS Asymptomatic CSF Down 10 C9-ALS, 6 C9-ALS Asymptomatic 56.4 ± 8.9 57.2 ± 8.7, 51.5 ± 18.5 N/A
CST4 P01036 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Up 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
CST3 P01034 Collins et al. 2015 ALS Control CSF Down 90 ALS, 80 control N/A N/A N/A
CST3 P01034 Iridoy et al. 2018 ALS Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8 N/A
CSRP3 P50461 Chia et al. 2025 ALS Control Plasma Up 231 ALS, 384 control (214 healthy control, 170 other neurological conditions) N/A 65.1 ± 10.8 N/A
CSRP3 P50461 Berrone et al. 2023 ALS Control Plasma Up 16 ALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS) N/A
CSRP1 P21291 Trautwig et al. 2025 C9orf72 ALS Control CSF Up 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
CSRP1 P21291 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CSRP1 P21291 Trautwig et al. 2025 C9orf72 ALS Sporadic ALS CSF Up 10 C9-ALS, 35 sALS 53.9 ± 11.5, 56.4 ± 8.9 56.7 ± 10.9, 57.2 ± 8.7 N/A
CSPG5 O95196 Trautwig et al. 2025 C9orf72 ALS Control CSF Down 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
CSPG4 Q6UVK1 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CSNK1D P48730 Oeckl et al. 2020 ALS Control Spinal cord Down 8 ALS, 7 control N/A 59 (52-61) 36 (24-90)
CSH1 P01243 Chen et al. 2016 ALS Control CSF Down 35 ALS, 10 control N/A 52.7 ±12.13 N/A
CSF3R Q99062 Berrone et al. 2023 sALS Control Plasma Up 8 sALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS) N/A
CSF2RA P15509 Barschke et al. 2020 C9-ALS C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls N/A 60 (51-67) N/A
CSF1R P07333 Trautwig et al. 2025 C9orf72 ALS C9orf72 ALS Asymptomatic CSF Up 10 C9-ALS, 6 C9-ALS Asymptomatic 56.4 ± 8.9 57.2 ± 8.7, 51.5 ± 18.5 N/A
CRYZL1 A6NMA8 Seyfried et al. 2018 ALS Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
CRYZ Q08257 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CRYM Q14894 Leoni et al. 2019 BO-ALS LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CRYM Q14894 Trautwig et al. 2025 C9orf72 ALS Asymptomatic Control CSF Up 6 C9-ALS Asymptomatic, 44 control N/A 51.5 ± 18.5 N/A
CRYL1 Q9Y2S2 Leoni et al. 2019 BO-ALS LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS) N/A N/A
CRYBG3 Q68DQ2 Collins et al. 2015 ALS Control CSF Up 90 ALS, 80 control N/A N/A N/A
CRYAB P02511 Trautwig et al. 2025 C9orf72 ALS Control CSF Up 10 C9-ALS, 44 control 56.4 ± 8.9 57.2 ± 8.7 N/A
CRYAB P02511 Iridoy et al. 2018 ALS Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8 N/A